Restoring Dystrophin via Exon Skipping Strategies -- PPMD 2022 Annual Conference
Prosensa's Video Animation on Exon Skipping
AVI Clinical Trial Update (3/2012)
Webinar: Viltepso - A Treatment Option for Patients Amenable to Exon 53 Skipping (April 2021)
In the Pipeline: Next-Gen Exon Skipping (PPMD's 2021 Virtual Annual Conference)
In the Pipeline: Restoring Dystrophin - Sarepta Therapeutics (RNA Targeted Therapies)
In the Pipeline: Restoring Dystrophin - Day 2 - PPMD Annual 2020
Direct Access: Sarepta, eteplirsen with Chris Garabedian (Oct 2012)
Duchenne Muscular Dystrophy (DMD) & Exondys 51 - JS Muscle Science
2022 FUTURES Exon Skipping and Read Through Agents Panel
Access Resource - EXONDYS 51 - California MediCal (Medicaid) Presentation
In the Pipeline: Dystrophin Restoration (PPMD's 2021 Virtual Annual Conference)
Experts Support Exondys 51
PepGen, Inc. Unlocking the Potential of Exon Skipping Therapeutics
PPMD 2018 Conference - Restoring or Replacing Dystrophin
How much promise does the drug Eteplirsen have for Duchenne muscular dystrophy? (Secret Scientist)
MDA Engage: Gene Therapy and Duchenne Muscular Dystrophy
Trial Update: Exon 53 NS-065/NCNP-01 - NS Pharma [PPMD's 2017 Connect Conference]
Potential Biomarkers and New Therapies for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) Mechanism of Disease